Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Arqule, Inc. (NQ: ARQL)
Streaming Delayed Price  /  Updated: 8:10 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(ARQL) Community Analysis from
April 20, 2014
(Stock Blog Hub, 1/16/13)
ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated...(read more)
(Stock Blog Hub, 1/18/12)
•    Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company's experimental treatment for liver cancer...(read more)
(Benzinga, 10/11/10)
ArQule, Inc. (Nasdaq: ARQL) today announced a Special Protocol Assessment agreement with the U.S. Food and Drug Administration for the design of a Phase 3 trial of ARQ 197 in patients with non-small cell lung cancer of non-squamous...(read more)
ArQule (ARQL) Company Overview

There is no analysis for ARQL yet. But you can go to Wikinvest to help create one!

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here